Genmab A/S Updates Articles of Association and Share Capital Authorizations

Genmab A/S filed a Form 6-K on June 15, 2026, to provide an updated English translation of its Articles of Association. The filing details the company's corporate structure, including its share capital of DKK 62,353,067 and various authorizations granted to the Board of Directors. Notably, the Board is authorized until March 12, 2029, to increase the share capital by up to DKK 6,600,000 and to issue convertible debt instruments. The articles also outline the framework for the company's warrant programs, which are used to incentivize employees and management. Additionally, the document defines the procedures for General Meetings, the composition and duties of the Board of Directors, and an indemnification scheme for Board members effective until 2029. The filing serves as a regulatory update on the company's governing rules and capital authorization status rather than announcing a new clinical or commercial milestone.